1-4 of 4
Kandasamy Hariharan
Close
Sort by
Journal Articles

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Henry Chan, Christina Trout, David Mikolon, Preston Adams, Roberto Guzman, Gustavo Fenalti, Konstantinos Mavrommatis, Mahan Abbasian, Lawrence Dearth, Brian Fox, Pallavur Sivakumar, Kandasamy Hariharan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2271.
https://doi.org/10.1182/blood-2021-147262
Published: 2021
Journal Articles

CD80 (B7.1) Is Expressed On Both Malignant B Cells and Tumor Infiltrating T Cells in Non-Hodgkin's Lymphomas.

Shabnam Tangri, Ph.D., Naveen Dakappagari, Annalee Estrellado, Andrew P. Weng, MD, PhD, Elizabeth Holmes, M. Wayne Saville, MD, FACP, FRCPA, Kandasamy Hariharan, Steffan Ho
Journal: Blood
Blood (2009) 114 (22): 1953.
https://doi.org/10.1182/blood.V114.22.1953.1953
Published: 2009
Journal Articles

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23 + lymphoma cell lines

Nuzhat I. Pathan, Peter Chu, Kandasamy Hariharan, Carolyn Cheney, Arturo Molina, John Byrd
Journal: Blood
Blood (2008) 111 (3): 1594–1602.
https://doi.org/10.1182/blood-2007-03-082024
Published: 2008
Journal Articles

Galiximab Sensitizes Malignant Human B Cell Lines to Apoptosis by Chemotherapeutic Drugs.

Stravroula Baritaki, Eriko Suzuki, Mario Vega, Steffan Ho, Kandasamy Hariharan, Benjamin Bonavida
Journal: Blood
Blood (2007) 110 (11): 3591.
https://doi.org/10.1182/blood.V110.11.3591.3591
Published: 2007